Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-[(4-Chloroanilino)sulfonyl]thiophene-2-carboxylic acid (STC)** is a small molecule organic compound classified as a sulfanilide. It features a thiophene ring substituted with a carboxylic acid group and a sulfamoyl group derived from 4-chlorophenyl, which contributes to its unique chemical properties and potential biological activities[7]. The compound has been investigated as an inhibitor of AmpC beta-lactamase, an enzyme that confers resistance to beta-lactam antibiotics in bacteria. Specifically, it acts as a non-beta-lactam inhibitor of class C beta-lactamase AmpC (Ki = 26 μM), providing insights into overcoming antibiotic resistance mechanisms[8]. While specific pharmacological data are limited, compounds in the sulfanilide class often exhibit antimicrobial properties by interfering with folic acid synthesis; however, direct evidence for this mechanism in STC is not established[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[(4-chloroanilino)sulfonyl]thiophene-2-carboxylic acid.